drugset
drugset / Trial / NCT02857426

A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)

NCT02857426 ↗

Phase 2 Completed 66 enrolled Bristol-Myers Squibb Ono Pharmaceutical Co., Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Nivolumab is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Timeline

Start
2016-10-21
Primary completion
2019-06-11
Completion
2020-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody — —

Indications

lymphoma